314732-37-1

Basic information

• Product Name: tert-butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate
• Synonyms: tert-butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate
• CAS NO: 314732-37-1
• Molecular Weight: 294.351
• Mol File: 314732-37-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate(314732-37-1)
• EPA Substance Registry System: tert-butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate(314732-37-1)

Safety Data

• Hazardous Substances Data: 314732-37-1(Hazardous Substances Data)

Upstream product

• 33233-67-9 4-(tert-Butoxycarbonylaminomethyl)benzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56-91-7 p-aminomethylbenzoic acid 

Downstream Products

• 1202804-50-9 1-(4-(aminomethyl)phenyl)ethanone trifluoroacetate salt 
• 1360616-36-9 tert-butyl 4-(oxazol-5-yl)benzylcarbamate 
• 1360616-38-1 (4-(oxazol-5-yl)phenyl)methanamine trifluoroacetate salt 
• 156866-52-3 tert-butyl N-(4-formylbenzyl)carbamate 
• 79533-04-3 tert-butyl 4-acetylbenzylcarbamate 

Relevant articles and documents

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction

E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity. However, the development of small-molecule inhibitors has proven extrao